ATAD2 and gastric cancer: Reiterating ATAD2’s involvement in the Rb/E2F pathway, a new study further demonstrates that in gastric cancer (GC) cells, suppression of ATAD2 delays the progression from G1 to S phase and lowers the production of cyclin D1, phosphorylated Rb (pRb), E2F1, and cyclin E. It has also been discovered that ATAD2 and E2F control the transcription of the proto-oncogene ACTR (AIB1/SRC-3/NCOA3) in BC cells [8].